With the continued uncertainty related to the COVID-19 pandemic, Diabetes Canada, CSEM, and the National Planning Committee have collectively decided to offer the 2021 Professional Conference as a virtual experience from November 23–26, 2021.

Registration is now open, click here!

Abstract submission is now open!

• Abstracts for the CSEM general endocrinology and metabolism program are now being accepted for the 2021 Diabetes Canada/CSEM Professional Conference. Submissions are accepted from researchers, endocrinologists and trainees. Submit within the next week to take advantage of the early bird rate for $25.00 per abstract until Wednesday, May 19, 2021, 5:00 PM EDT. After May 19, the regular fee will be $45.00. Abstract submission closes on Wednesday, June 2, 2021, 11:59 PM EDT. Click here to submit a general abstract.
• CSEM is now accepting abstracts for resident clinical vignettes or proposed/in-progress basic science or translational research projects. Oral presentations and e-posters will be pre-recorded and presented virtually during the 2021 Diabetes Canada/CSEM Professional Conference. Submission deadline: Monday, September 6, 2021 at 11:59 PM EDT. Click here to submit a resident clinical vignette or proposed research project abstract.

The conference website will updated as more information becomes available.

CSEM has received questions from its members regarding the eligibility and safety of the COVID-19 vaccines and patients with endocrine conditions. Health Canada recommendations are changing rapidly. Recognizing there is little data to address groups excluded in the vaccine trials, a risk benefit assessment will need to be case-by-case and in consideration of national, provincial and local regulations.

CSEM supports equitable access to COVID-19 vaccines for individuals with endocrine conditions. Patients with type 1 diabetes, other autoimmune conditions, and immunocompromised health should have a risk/benefit discussion with their health care provider to make an informed decision. Some patients have multiple comorbidities that affect their vaccine status and patients may need to discuss with the relevant specialist(s).

Please see our statement for resources and references, including Diabetes Canada's statement.

View the CSEM 2020 Annual Report here.

Renew Your Membership

Your CSEM membership expires January 15, 2021. Don't miss out on important updates and stay connected with your colleagues. Renew online now.

Not only do CSEM members get discounts at the Diabetes Canada/CSEM Professional Conference and other meetings, your membership also allows you to:

• contribute and collaborate with a network of endocrinologists across Canada;
• build your career potential through a united community;
• vote and take part in CSEM committees and leadership roles;
• stay connected and informed about the latest in endocrinology and metabolism, educational opportunities and events.

CSEM values your membership. It is only through a strong and engaged member base that we can effectively advocate for excellence in endocrinology research, education, and patient care, and advance the discipline of endocrinology and metabolism in Canada.

RESOURCES FOR PHYSICIANS

General Info

• Choosing Wisely Canada: COVID-19 Recommendations (for the public and for clinicians)
• Health Canada: Clinical management of patients with COVID-19: Second interim guidance
• Up-to-date info: Public Health Agency of Canada: Coronavirus disease (COVID-19): For health professionals
• Latest news: CMAJ's COVID-19 page

Pre-existing Conditions and COVID-19

• Androgen replacement: Guidance on androgen replacement during COVID-19 crisis
• Diabetes:
  • Diabetes Canada: FAQ about COVID-19 and diabetes
  • Association of British Clinical Diabetologists (ABCD): COVID-19 resources for proofessionals
  • COVID-19 and childhood diabetes
  • Coronavirus + Diabetes
  • University of Toronto, Family & Community Medicine: Managing type 2 diabetes during COVID-19: a guide for primary care providers
• Diabetes insipidus: Society for Endocrinology: Endocrinology in the time of COVID-19: Management of hyponatraemia and diabetes insipidus
• Fertility treatment: Template for advising patients receiving treatment for male infertility
• Genetic haemochromatosis: Haemochromatosis UK: Guidance for people with genetic haemochromatosis during COVID-19 pandemic
• Growth hormone: Guidance on adult growth hormone (GH) replacement therapy during the COVID-19 pandemic
• Neuroendocrine tumours: COVID-19 pandemic strategy for the interim management of patients with neuroendocrine tumours/neuroendocrine cancer
• Osteoporosis and calcium disorders:
  • Society for Endocrinology: Endocrinology in the time of COVID-19: Management of calcium disorders and osteoporosis
  • LETTER TEMPLATE - Continuation of denosumab (Prolia®) injection during the COVID-19 pandemic (hospital administration)
  • LETTER TEMPLATE - Self-administration of denosumab (Prolia®) during the COVID-19 pandemic
  • LETTER TEMPLATE - Postponement of zoledronic acid infusions
  • Royal Osteoporosis Society (UK): Advice and information page for osteoporosis
• Parathyroid: Parathyroid UK: Coronavirus (COVID-19) and parathyroid conditions FAQs
• Pituitary/adrenal insufficiency:
  • Royal College of Physicians (UK): Guidance for the prevention and emergency management of adult patients with adrenal insufficiency
  • National Adrenal Diseases Foundation: COVID-19 – Adrenal Insufficiency and Steroid Dosing Guidelines
  • Canadian Addison Society:
    • National Adrenal Crisis Emergency Cards (bilingual)
    • Links about adrenal insufficiency and coronavirus
  • Addison's Self-Help Group (UK):
    • COVID-19: Clinical Management guidance: Adrenal Insufficiency
    • Emergency Training video: Solu-Cortef, Act-o-Vial safety syringe emergency injection
  • Society for Endocrinology:
    • Advice for patients who take replacement steroids (hydrocortisone, prednisolone, dexamethasone or plenadren) for pituitary/adrenal insufficiency
    • Endocrinology in the time of COVID-19: Management of adrenal insufficiency
    • Endocrinology in the time of COVID-19: Management of Cushing's syndrome
  • Pituitary Foundation (UK): Hydrocortisone advice for parents leaflet
• Pituitary tumours:
  • Society for Endocrinology: Endocrinology in the time of COVID-19: Management of pituitary tumours
• Thyroid dysfunction:
  • BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID-19 pandemic
  • Resource-limited treatment of thyrotoxicosis during the COVID-19 pandemic
  • LETTER TEMPLATE - Cancellation of your radioactive iodine treatment (131-I) for hyperthyroidism
  • JCEM: Subacute thyroiditis after Sars-COV-2 infection
• Thyroid cancer:
  • BTA/SFE advice for patients with thyroid cancer during the COVID-19 pandemic
  • LETTER TEMPLATE - Thyroid cancer: radioactive iodine rreatment during COVID-19 pandemic

Kids with Endocrine Conditions and School:

• Canadian School Boards Association: Reopening of schools post COVID-19
• BC Centre for Disease Control: COVID-19 public health guidance for K–12 school settings
• BC Children's Hospital: COVID-19 and adrenal insufficiency
• Canadian Paediatric Society: CPS supports a safe return to school for Canada’s children and youth
• diabetes@school: Type 1 diabetes and COVID-19: going back to school

Practice Issues

• Canadian Medical Protective Association COVID-19: Scope of practice, virtual care or medical legal issues
• Royal College of Physicians and Surgeons of Canada: Telemedicine and virtual care guidelines (and other clinical resources for COVID-19)
• Canadian Medical Association:
  • How to set up virtual care in your practice
  • Policy: Framework for ethical decision-making during the coronavirus pandemic

Health and Wellness

• Canadian Medical Protective Association: Resources for staying well during COVID-19
• Canadian Medical Association:
  • A clinician’s guide: Managing COVID-19 stress and anxiety
  • Maintaining your and your family’s well-being during a pandemic

Financial Matters

• Canada Revenue Agency: COVID-19: Changes to Canadian taxes and benefits
• MD Financial Management: Here for you during COVID-19